Briefing
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
A prespecified secondary analysis of the DAPHNe trial assessed 5-year outcomes and ultrasensitive ctDNA dynamics in ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. A Personalis author affiliation is on the PubMed record.
- Design: Evidence level 2
- Assay: Personalis